Gabelli & Co Investment Advisers’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-67,261	Closed	-$753K	–	199
2017 Q3	$753K	Sell	67,261 -35,000	-34%	-$386K	0.09%	91
2017 Q2	$1.13M	Buy	+102,261	New	+$1.02M	0.12%	75

Gabelli & Co Investment Advisers's SCLN Position: Q4 2017 in Review

Gabelli & Co Investment Advisers sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 67,261 shares — an estimated $753K sold.

Gabelli & Co Investment Advisers first reported a position in SCLN in Q2 2017 and held it in 2 quarters. The position peaked at $1.13M in Q2 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.

Gabelli & Co Investment Advisers reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
Gabelli & Co Investment Advisers sold 67,261 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $753K.
Gabelli & Co Investment Advisers first reported a position in Sciclone Pharmaceuticals Inc in Q2 2017 and held it in 2 quarters.
Gabelli & Co Investment Advisers's Sciclone Pharmaceuticals Inc position peaked at $1.13M in Q2 2017.
0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.

Based on Gabelli & Co Investment Advisers's 13F filing for Q4 2017, filed 2 Feb 2018.